APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

FGF-2 Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global FGF-2 Inhibitors Market Outlook and Growth Opportunities 2026

Report ID 173991550430 December 2025206 pages

Choose your research edition.

Industry ResearchFGF-2 Inhibitors Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal FGF-2 Inhibitors Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal FGF-2 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal FGF-2 Inhibitors Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal FGF-2 Inhibitors Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global FGF-2 Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for FGF-2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for FGF-2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for FGF-2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the FGF-2 Inhibitors market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the FGF-2 Inhibitors market include Advenchen Laboratories, ArQule, AVEO Pharmaceuticals, Batu Biologics, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celon Pharma, Debiopharm International and Eddingpharm, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global FGF-2 Inhibitors market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of FGF-2 Inhibitors and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents FGF-2 Inhibitors revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global FGF-2 Inhibitors market.

FGF-2 Inhibitors Segment by Company

Advenchen Laboratories

ArQule

AVEO Pharmaceuticals

Batu Biologics

Boehringer Ingelheim

Bristol-Myers Squibb Company

Celon Pharma

Debiopharm International

Eddingpharm

Eli Lilly and Company

Hutchison MediPharma

Principia Biopharma

Santa Cruz Biotechnology

Vichem Chemie Research

AstraZeneca

Amgen

Novartis

Eisai

FGF-2 Inhibitors Segment by Type

EDP-317

Debio-1347

CPL-043

BAY-1163877

AZD-4547

ASP-5878

Others

FGF-2 Inhibitors Segment by Application

Clinic

Hospital

Others

FGF-2 Inhibitors Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global FGF-2 Inhibitors status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the FGF-2 Inhibitors key companies, revenue, market share, and recent developments.

3. To split the FGF-2 Inhibitors breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions FGF-2 Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify FGF-2 Inhibitors significant trends, drivers, influence factors in global and regions.

6. To analyze FGF-2 Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global FGF-2 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of FGF-2 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of FGF-2 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global FGF-2 Inhibitors industry.

Chapter 3: Detailed analysis of FGF-2 Inhibitors company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of FGF-2 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of FGF-2 Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. FGF-2 Inhibitors Industry Trends Table 2. FGF-2 Inhibitors Industry Drivers Table 3. FGF-2 Inhibitors Industry Opportunities and Challenges Table 4. FGF-2 Inhibitors Industry Restraints Table 5. Global FGF-2 Inhibitors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global FGF-2 Inhibitors Revenue Share by Company (2021-2026) Table 7. Global FGF-2 Inhibitors Company Ranking, (2024-2026) & (US$ Million) Table 8. Global FGF-2 Inhibitors Key Company Manufacturing Base & Headquarters Table 9. Global FGF-2 Inhibitors Company, Product Type & Application Table 10. Global FGF-2 Inhibitors Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global FGF-2 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of EDP-317 Table 15. Significant Companies of Debio-1347 Table 16. Significant Companies of CPL-043 Table 17. Significant Companies of BAY-1163877 Table 18. Significant Companies of AZD-4547 Table 19. Significant Companies of ASP-5878 Table 20. Significant Companies of Others Table 21. Global FGF-2 Inhibitors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 22. Global FGF-2 Inhibitors Sales Value by Type (2021-2026) & (US$ Million) Table 23. Global FGF-2 Inhibitors Sales Value by Type (2027-2032) & (US$ Million) Table 24. Global FGF-2 Inhibitors Sales Value Share by Type (2021-2026) Table 25. Global FGF-2 Inhibitors Sales Value Share by Type (2027-2032) Table 26. Significant Companies of Clinic Table 27. Significant Companies of Hospital Table 28. Significant Companies of Others Table 29. Global FGF-2 Inhibitors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global FGF-2 Inhibitors Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global FGF-2 Inhibitors Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global FGF-2 Inhibitors Sales Value Share by Application (2021-2026) Table 33. Global FGF-2 Inhibitors Sales Value Share by Application (2027-2032) Table 34. Global FGF-2 Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global FGF-2 Inhibitors Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global FGF-2 Inhibitors Sales Value Share by Region (2021-2026) Table 37. Global FGF-2 Inhibitors Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global FGF-2 Inhibitors Sales Value Share by Region (2027-2032) Table 39. Global FGF-2 Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global FGF-2 Inhibitors Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global FGF-2 Inhibitors Sales Value Market Share by Country (2021-2026) Table 42. Global FGF-2 Inhibitors Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global FGF-2 Inhibitors Sales Value Market Share by Country (2027-2032) Table 44. Advenchen Laboratories Company Information Table 45. Advenchen Laboratories Business Overview Table 46. Advenchen Laboratories FGF-2 Inhibitors Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Advenchen Laboratories FGF-2 Inhibitors Product Portfolio Table 48. Advenchen Laboratories Recent Development Table 49. ArQule Company Information Table 50. ArQule Business Overview Table 51. ArQule FGF-2 Inhibitors Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. ArQule FGF-2 Inhibitors Product Portfolio Table 53. ArQule Recent Development Table 54. AVEO Pharmaceuticals Company Information Table 55. AVEO Pharmaceuticals Business Overview Table 56. AVEO Pharmaceuticals FGF-2 Inhibitors Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. AVEO Pharmaceuticals FGF-2 Inhibitors Product Portfolio Table 58. AVEO Pharmaceuticals Recent Development Table 59. Batu Biologics Company Information Table 60. Batu Biologics Business Overview Table 61. Batu Biologics FGF-2 Inhibitors Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Batu Biologics FGF-2 Inhibitors Product Portfolio Table 63. Batu Biologics Recent Development Table 64. Boehringer Ingelheim Company Information Table 65. Boehringer Ingelheim Business Overview Table 66. Boehringer Ingelheim FGF-2 Inhibitors Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Boehringer Ingelheim FGF-2 Inhibitors Product Portfolio Table 68. Boehringer Ingelheim Recent Development Table 69. Bristol-Myers Squibb Company Company Information Table 70. Bristol-Myers Squibb Company Business Overview Table 71. Bristol-Myers Squibb Company FGF-2 Inhibitors Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Bristol-Myers Squibb Company FGF-2 Inhibitors Product Portfolio Table 73. Bristol-Myers Squibb Company Recent Development Table 74. Celon Pharma Company Information Table 75. Celon Pharma Business Overview Table 76. Celon Pharma FGF-2 Inhibitors Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Celon Pharma FGF-2 Inhibitors Product Portfolio Table 78. Celon Pharma Recent Development Table 79. Debiopharm International Company Information Table 80. Debiopharm International Business Overview Table 81. Debiopharm International FGF-2 Inhibitors Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Debiopharm International FGF-2 Inhibitors Product Portfolio Table 83. Debiopharm International Recent Development Table 84. Eddingpharm Company Information Table 85. Eddingpharm Business Overview Table 86. Eddingpharm FGF-2 Inhibitors Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Eddingpharm FGF-2 Inhibitors Product Portfolio Table 88. Eddingpharm Recent Development Table 89. Eli Lilly and Company Company Information Table 90. Eli Lilly and Company Business Overview Table 91. Eli Lilly and Company FGF-2 Inhibitors Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Eli Lilly and Company FGF-2 Inhibitors Product Portfolio Table 93. Eli Lilly and Company Recent Development Table 94. Hutchison MediPharma Company Information Table 95. Hutchison MediPharma Business Overview Table 96. Hutchison MediPharma FGF-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Hutchison MediPharma FGF-2 Inhibitors Product Portfolio Table 98. Hutchison MediPharma Recent Development Table 99. Principia Biopharma Company Information Table 100. Principia Biopharma Business Overview Table 101. Principia Biopharma FGF-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Principia Biopharma FGF-2 Inhibitors Product Portfolio Table 103. Principia Biopharma Recent Development Table 104. Santa Cruz Biotechnology Company Information Table 105. Santa Cruz Biotechnology Business Overview Table 106. Santa Cruz Biotechnology FGF-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Santa Cruz Biotechnology FGF-2 Inhibitors Product Portfolio Table 108. Santa Cruz Biotechnology Recent Development Table 109. Vichem Chemie Research Company Information Table 110. Vichem Chemie Research Business Overview Table 111. Vichem Chemie Research FGF-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Vichem Chemie Research FGF-2 Inhibitors Product Portfolio Table 113. Vichem Chemie Research Recent Development Table 114. AstraZeneca Company Information Table 115. AstraZeneca Business Overview Table 116. AstraZeneca FGF-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. AstraZeneca FGF-2 Inhibitors Product Portfolio Table 118. AstraZeneca Recent Development Table 119. Amgen Company Information Table 120. Amgen Business Overview Table 121. Amgen FGF-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Amgen FGF-2 Inhibitors Product Portfolio Table 123. Amgen Recent Development Table 124. Novartis Company Information Table 125. Novartis Business Overview Table 126. Novartis FGF-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Novartis FGF-2 Inhibitors Product Portfolio Table 128. Novartis Recent Development Table 129. Eisai Company Information Table 130. Eisai Business Overview Table 131. Eisai FGF-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Eisai FGF-2 Inhibitors Product Portfolio Table 133. Eisai Recent Development Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. FGF-2 Inhibitors Product Image Figure 2. Global FGF-2 Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global FGF-2 Inhibitors Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. EDP-317 Image Figure 8. Debio-1347 Image Figure 9. CPL-043 Image Figure 10. BAY-1163877 Image Figure 11. AZD-4547 Image Figure 12. ASP-5878 Image Figure 13. Others Image Figure 14. Global FGF-2 Inhibitors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global FGF-2 Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global FGF-2 Inhibitors Sales Value Share by Type (2021-2032) Figure 17. Clinic Image Figure 18. Hospital Image Figure 19. Others Image Figure 20. Global FGF-2 Inhibitors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global FGF-2 Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global FGF-2 Inhibitors Sales Value Share by Application (2021-2032) Figure 23. Global FGF-2 Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global FGF-2 Inhibitors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America FGF-2 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 26. North America FGF-2 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe FGF-2 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 28. Europe FGF-2 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific FGF-2 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific FGF-2 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America FGF-2 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 32. South America FGF-2 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa FGF-2 Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa FGF-2 Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt FGF-2 Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • EDP-317
  • Debio-1347
  • CPL-043
  • BAY-1163877
  • AZD-4547
  • ASP-5878
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Advenchen Laboratories
  • ArQule
  • AVEO Pharmaceuticals
  • Batu Biologics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Celon Pharma
  • Debiopharm International
  • Eddingpharm
  • Eli Lilly and Company
  • Hutchison MediPharma
  • Principia Biopharma
  • Santa Cruz Biotechnology
  • Vichem Chemie Research
  • AstraZeneca
  • Amgen
  • Novartis
  • Eisai

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global FGF-2 Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global FGF-2 Inhibitors Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 FGF-2 Inhibitors Market Dynamics
  1. 2.1 FGF-2 Inhibitors Industry Trends
  2. 2.2 FGF-2 Inhibitors Industry Drivers
  3. 2.3 FGF-2 Inhibitors Industry Opportunities and Challenges
  4. 2.4 FGF-2 Inhibitors Industry Restraints
3 FGF-2 Inhibitors Market by Company
  1. 3.1 Global FGF-2 Inhibitors Company Revenue Ranking in 2025
  2. 3.2 Global FGF-2 Inhibitors Revenue by Company (2021-2026)
  3. 3.3 Global FGF-2 Inhibitors Company Ranking (2024-2026)
  4. 3.4 Global FGF-2 Inhibitors Company Manufacturing Base and Headquarters
  5. 3.5 Global FGF-2 Inhibitors Company Product Type and Application
  6. 3.6 Global FGF-2 Inhibitors Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global FGF-2 Inhibitors Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 FGF-2 Inhibitors Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 FGF-2 Inhibitors Market by Type
  1. 4.1 FGF-2 Inhibitors Type Introduction
  2. 4.1.1 EDP-317
  3. 4.1.2 Debio-1347
  4. 4.1.3 CPL-043
  5. 4.1.4 BAY-1163877
  6. 4.1.5 AZD-4547
  7. 4.1.6 ASP-5878
  8. 4.1.7 Others
  9. 4.2 Global FGF-2 Inhibitors Sales Value by Type
  10. 4.2.1 Global FGF-2 Inhibitors Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global FGF-2 Inhibitors Sales Value by Type (2021-2032)
  12. 4.2.3 Global FGF-2 Inhibitors Sales Value Share by Type (2021-2032)
5 FGF-2 Inhibitors Market by Application
  1. 5.1 FGF-2 Inhibitors Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global FGF-2 Inhibitors Sales Value by Application
  6. 5.2.1 Global FGF-2 Inhibitors Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global FGF-2 Inhibitors Sales Value by Application (2021-2032)
  8. 5.2.3 Global FGF-2 Inhibitors Sales Value Share by Application (2021-2032)
6 FGF-2 Inhibitors Regional Value Analysis
  1. 6.1 Global FGF-2 Inhibitors Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global FGF-2 Inhibitors Sales Value by Region (2021-2032)
  3. 6.2.1 Global FGF-2 Inhibitors Sales Value by Region: 2021-2026
  4. 6.2.2 Global FGF-2 Inhibitors Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America FGF-2 Inhibitors Sales Value (2021-2032)
  7. 6.3.2 North America FGF-2 Inhibitors Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe FGF-2 Inhibitors Sales Value (2021-2032)
  10. 6.4.2 Europe FGF-2 Inhibitors Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific FGF-2 Inhibitors Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific FGF-2 Inhibitors Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America FGF-2 Inhibitors Sales Value (2021-2032)
  16. 6.6.2 South America FGF-2 Inhibitors Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa FGF-2 Inhibitors Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa FGF-2 Inhibitors Sales Value Share by Country, 2025 VS 2032
7 FGF-2 Inhibitors Country-level Value Analysis
  1. 7.1 Global FGF-2 Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global FGF-2 Inhibitors Sales Value by Country (2021-2032)
  3. 7.2.1 Global FGF-2 Inhibitors Sales Value by Country (2021-2026)
  4. 7.2.2 Global FGF-2 Inhibitors Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt FGF-2 Inhibitors Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt FGF-2 Inhibitors Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt FGF-2 Inhibitors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Advenchen Laboratories
  2. 8.1.1 Advenchen Laboratories Company Information
  3. 8.1.2 Advenchen Laboratories Business Overview
  4. 8.1.3 Advenchen Laboratories FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Advenchen Laboratories FGF-2 Inhibitors Product Portfolio
  6. 8.1.5 Advenchen Laboratories Recent Developments
  7. 8.2 ArQule
  8. 8.2.1 ArQule Company Information
  9. 8.2.2 ArQule Business Overview
  10. 8.2.3 ArQule FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  11. 8.2.4 ArQule FGF-2 Inhibitors Product Portfolio
  12. 8.2.5 ArQule Recent Developments
  13. 8.3 AVEO Pharmaceuticals
  14. 8.3.1 AVEO Pharmaceuticals Company Information
  15. 8.3.2 AVEO Pharmaceuticals Business Overview
  16. 8.3.3 AVEO Pharmaceuticals FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AVEO Pharmaceuticals FGF-2 Inhibitors Product Portfolio
  18. 8.3.5 AVEO Pharmaceuticals Recent Developments
  19. 8.4 Batu Biologics
  20. 8.4.1 Batu Biologics Company Information
  21. 8.4.2 Batu Biologics Business Overview
  22. 8.4.3 Batu Biologics FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Batu Biologics FGF-2 Inhibitors Product Portfolio
  24. 8.4.5 Batu Biologics Recent Developments
  25. 8.5 Boehringer Ingelheim
  26. 8.5.1 Boehringer Ingelheim Company Information
  27. 8.5.2 Boehringer Ingelheim Business Overview
  28. 8.5.3 Boehringer Ingelheim FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Boehringer Ingelheim FGF-2 Inhibitors Product Portfolio
  30. 8.5.5 Boehringer Ingelheim Recent Developments
  31. 8.6 Bristol-Myers Squibb Company
  32. 8.6.1 Bristol-Myers Squibb Company Company Information
  33. 8.6.2 Bristol-Myers Squibb Company Business Overview
  34. 8.6.3 Bristol-Myers Squibb Company FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bristol-Myers Squibb Company FGF-2 Inhibitors Product Portfolio
  36. 8.6.5 Bristol-Myers Squibb Company Recent Developments
  37. 8.7 Celon Pharma
  38. 8.7.1 Celon Pharma Company Information
  39. 8.7.2 Celon Pharma Business Overview
  40. 8.7.3 Celon Pharma FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Celon Pharma FGF-2 Inhibitors Product Portfolio
  42. 8.7.5 Celon Pharma Recent Developments
  43. 8.8 Debiopharm International
  44. 8.8.1 Debiopharm International Company Information
  45. 8.8.2 Debiopharm International Business Overview
  46. 8.8.3 Debiopharm International FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Debiopharm International FGF-2 Inhibitors Product Portfolio
  48. 8.8.5 Debiopharm International Recent Developments
  49. 8.9 Eddingpharm
  50. 8.9.1 Eddingpharm Company Information
  51. 8.9.2 Eddingpharm Business Overview
  52. 8.9.3 Eddingpharm FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Eddingpharm FGF-2 Inhibitors Product Portfolio
  54. 8.9.5 Eddingpharm Recent Developments
  55. 8.10 Eli Lilly and Company
  56. 8.10.1 Eli Lilly and Company Company Information
  57. 8.10.2 Eli Lilly and Company Business Overview
  58. 8.10.3 Eli Lilly and Company FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eli Lilly and Company FGF-2 Inhibitors Product Portfolio
  60. 8.10.5 Eli Lilly and Company Recent Developments
  61. 8.11 Hutchison MediPharma
  62. 8.11.1 Hutchison MediPharma Company Information
  63. 8.11.2 Hutchison MediPharma Business Overview
  64. 8.11.3 Hutchison MediPharma FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Hutchison MediPharma FGF-2 Inhibitors Product Portfolio
  66. 8.11.5 Hutchison MediPharma Recent Developments
  67. 8.12 Principia Biopharma
  68. 8.12.1 Principia Biopharma Company Information
  69. 8.12.2 Principia Biopharma Business Overview
  70. 8.12.3 Principia Biopharma FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Principia Biopharma FGF-2 Inhibitors Product Portfolio
  72. 8.12.5 Principia Biopharma Recent Developments
  73. 8.13 Santa Cruz Biotechnology
  74. 8.13.1 Santa Cruz Biotechnology Company Information
  75. 8.13.2 Santa Cruz Biotechnology Business Overview
  76. 8.13.3 Santa Cruz Biotechnology FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Santa Cruz Biotechnology FGF-2 Inhibitors Product Portfolio
  78. 8.13.5 Santa Cruz Biotechnology Recent Developments
  79. 8.14 Vichem Chemie Research
  80. 8.14.1 Vichem Chemie Research Company Information
  81. 8.14.2 Vichem Chemie Research Business Overview
  82. 8.14.3 Vichem Chemie Research FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Vichem Chemie Research FGF-2 Inhibitors Product Portfolio
  84. 8.14.5 Vichem Chemie Research Recent Developments
  85. 8.15 AstraZeneca
  86. 8.15.1 AstraZeneca Company Information
  87. 8.15.2 AstraZeneca Business Overview
  88. 8.15.3 AstraZeneca FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  89. 8.15.4 AstraZeneca FGF-2 Inhibitors Product Portfolio
  90. 8.15.5 AstraZeneca Recent Developments
  91. 8.16 Amgen
  92. 8.16.1 Amgen Company Information
  93. 8.16.2 Amgen Business Overview
  94. 8.16.3 Amgen FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Amgen FGF-2 Inhibitors Product Portfolio
  96. 8.16.5 Amgen Recent Developments
  97. 8.17 Novartis
  98. 8.17.1 Novartis Company Information
  99. 8.17.2 Novartis Business Overview
  100. 8.17.3 Novartis FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Novartis FGF-2 Inhibitors Product Portfolio
  102. 8.17.5 Novartis Recent Developments
  103. 8.18 Eisai
  104. 8.18.1 Eisai Company Information
  105. 8.18.2 Eisai Business Overview
  106. 8.18.3 Eisai FGF-2 Inhibitors Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Eisai FGF-2 Inhibitors Product Portfolio
  108. 8.18.5 Eisai Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst